Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Matinas BioPharma Holdings Inc
6LJCurrent price
2.69 EUR
0 EUR (0.00%)
Last closed
3.71 USD
Company
www.matinasbiopharma.com
ISIN
US5768101058
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
19 262 668 USD
Yield for 12 month
-48.61 %
1Y
3Y
5Y
10Y
15Y
6LJ
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey. Address: 1545 Route 206 South, Bedminster, NJ, United States, 07921
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
40 USDP/E ratio
–Dividend Yield
–Current Year
+1 096 000 USD
Last Year
+3 188 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+155 000 USD
Last Year
-13 490 000 USD
Current Quarter
-241 000 USD
Last Quarter
-240 000 USD
Key Figures 6LJ
1 year
3 years
5 years
10 years
EBITDA
-23 378 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-50.87 %
PEG Ratio
–
Return On Equity TTM
-97.59 %
Wall Street Target Price
40 USD
Revenue TTM
–
Book Value
3.81 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
-13 490 000 USD
Earnings per share
-5.5 USD
Diluted Eps TTM
-5.5 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 6LJ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 6LJ
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:50
Payout Ratio
–
Last Split Date
03.09.2024
Dividend Date
–
Stock Valuation 6LJ
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
37.1951
Price Sales TTM
46.5017
Enterprise Value EBITDA
-1.786
Price Book MRQ
1.0084
Financials 6LJ
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 6LJ
For 52 weeks
3.28 USD
44.5 USD
50 Day MA
6.77 USD
Shares Short Prior Month
27 433
200 Day MA
9.57 USD
Short Ratio
1.84
Shares Short
57 716
Short Percent
1.18 %
BeatStart